Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We evaluated hypoxia inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) expression and their prognostic significance in diffuse large B-cell lymphoma (DLBCL). Expression of HIF-1α and VEGF was studied in 78 patients and results correlated with clinicopathological and prognostic data. HIF-1α and VEGF were expressed in 67% and 84% of patients, respectively, and a significant correlation was demonstrated between them (p < 0.001). Outcome was analyzed according to treatment. HIF-1α positive patients given rituximab demonstrated improved outcome, with 5-year overall survival of 72% for those receiving rituximab versus 65% for those not receiving rituximab, and 5-year progression-free survival (PFS) 76% versus 57%. No correlation was demonstrated between HIF-1α and other prognostic biomarkers including BCL6, CD10 and MUM-1. We demonstrated significantly improved PFS (p = 0.003) in patients receiving rituximab and showing BCL6 overexpression. The results confirm the significant association between HIF-1α and VEGF expression and suggest that HIF-1α expression is a favorable prognostic factor in patients with DLBCL treated with rituximab.

Original publication

DOI

10.3109/10428194.2012.733875

Type

Journal article

Journal

Leuk Lymphoma

Publication Date

05/2013

Volume

54

Pages

959 - 966

Keywords

Adult, Aged, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Agents, Biomarkers, Female, Gene Expression, Humans, Hypoxia-Inducible Factor 1, alpha Subunit, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged, Neoplasm Staging, Prognosis, Retrospective Studies, Rituximab, Treatment Outcome, Vascular Endothelial Growth Factor A